Understand the source comparison
Cartalax vs Thymalin: Mechanism Comparison
Primary Target Tissue Gastric mucosa (stomach lining epithelial cells) Thymus gland and peripheral T-lymphocytes Non-overlapping tissue targets. Not interchangeable Mechanism of Action Peptide receptor signaling at gastric epithelial cells, upregulating cytopr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Target Tissue
- Gastric mucosa (stomach lining epithelial cells)
- Thymus gland and peripheral T-lymphocytes
- Non-overlapping tissue targets. Not interchangeable
- Mechanism of Action
- Peptide receptor signaling at gastric epithelial cells, upregulating cytoprotective gene expression and mucosal regeneration
- Thymic hormone replacement restoring T-cell differentiation pathways disrupted by thymic involution
- Cartalax = localized repair; Thymalin = systemic immune restoration
- Half-Life
- Approximately 2–4 hours (rapidly metabolized locally)
- Approximately 6–8 hours (systemic circulation with thymic tissue accumulation)
- Cartalax requires more frequent dosing due to shorter half-life
- Standard Research Dosing
- 0.1–0.5 mg per administration, daily for 10–20 days
- 5–10 mg per administration, daily for 5–10 days
- Thymalin uses higher absolute doses due to systemic distribution
- Onset of Observable Effects
- 48–72 hours (epithelial cell proliferation markers)
- 7–10 days (T-cell count elevation)
- Cartalax shows faster localized effects; Thymalin requires immune cell maturation time
- Contraindications
- None documented in standard research protocols
- Autoimmune disorders, hyperthyroidism, acute infections
- Thymalin carries immune-specific contraindications due to T-cell upregulation